Stock Market & Financial Investment News

News Breaks October 23, 2012 08:15 EDT MRK, SNY FDA warning on Ambien would benefit Merck, says JPMorgan JPMorgan says the potential FDA safety warning on Sanofi's (SNY) Ambien could be positive for Merck's (MRK) insomnia treatment candidate suvorexant. The firm says its physician survey suggests such a warning would change Ambien prescribing habits and keeps an Overweight rating on shares of Merck. News For MRK;SNY From The Last 14 Days Check below for free stories on MRK;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 16, 2013 08:55 EDT MRK BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 15, 2013 15:16 EDT SNY Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information 05:39 EDT SNY Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information May 14, 2013 17:39 EDT MRK Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. May 13, 2013 09:44 EDT SNY Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:30 EDT SNY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. May 10, 2013 11:48 EDT MRK, SNY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 06:53 EDT MRK GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says Subscribe for More Information May 9, 2013 07:22 EDT MRK Merck awarded significant portion of UNICEF HPV vaccine tender Subscribe for More Information May 8, 2013 08:32 EDT MRK Merck says FDA accepts biologics license application for allergy tablet Merck announced that the Biologics License Application for its investigational ragweed pollen sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014. May 6, 2013 08:53 EDT MRK BofA/Merrill's major pharma analysts hold an analyst/industry conference call Subscribe for More Information 07:49 EDT SNY Bernstein's global pharmaceuticals analyst has analyst/industry conference call Subscribe for More Information 07:18 EDT MRK American Congress of Obstetrics and Gynecology to hold annual meeting Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.